Abstract 492P
Background
The third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is a standard treatment in case of T790M mutation positive after failure to first or second generation EGFR TKI in patients with EGFR-mutant non-small cell lung cancer (NSCLC). We investigated a success rate of rebiopsy and sequential EGFR TKI treatment in real world setting in Korea.
Methods
We retrospectively reviewed medical records of patients with EGFR mutant advanced NSCLC who received first- or second- generation EGFR TKI between Jan 2012 and Jun 2018 at a single center in Korea.
Results
Among 221 patients with EGFR-mutant NSCLC, 68 patients who were lost to follow up (n = 19) or still on 1st- or 2nd- generation TKI (n = 49) at time of analysis were excluded. Forty-three out of remaining 153 patients (28%) did not have a chance of consideration for second line treatment because of deterioration of performance status (n = 21) or death (n = 22), especially in elderly over 70 years. Tests for acquired EGFR mutation were performed in 76% (84/110), among which 73 cases were tissue rebiopsy and 11 cases were plasma EGFR mutation analysis. Acquisition of tumor tissue in rebiopsy was successful in 93% (68/73). The most common reason of not doing rebiopsy was lack of sequential treatment options (n = 24). Ten patients with negative T790M or failure at initial rebiopsy underwent more than two times of repeated EGFR mutation analysis, among which four patients had eventually positive T790M at some point of disease course. Overall T790M positive rate was 54% (45/84). Among 7 patients with initially negative T790M mutation in plasma analysis, further rebiopsy from tumor tissue was performed only in one patients because of patient's refusal (n = 2), physician's decision to continue post-progression EGFR TKI (n = 2), poor performance status (n = 1), and unaccessibility to tumor tissue (n = 1).
Conclusions
About 30% of patients with EGFR mutant NSCLC did not have a chance of consideration for second line EGFR TKI treatment, especially in elderly over 70 years. Success rate of tumor tissue rebiopsy was over 90% in real world setting, and repeated rebiopsy may increase detection rate of acquired T790M mutation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
97P - The role of adjuvant chemotherapy according to the status of surgical margin in rectal cancer
Presenter: Jong Hoon Lee
Session: Poster display session
Resources:
Abstract
98P - Influence of DPYD*9, DPYD*6 and GSTP1 ile105val genetic polymorphisms on capecitabine and oxaliplatin (CAPOX) associated toxicities in colorectal cancer patients
Presenter: Ashok Varma
Session: Poster display session
Resources:
Abstract
99P - Patient-derived tumour model by new culture method leading to the precision medicine
Presenter: Norikatsu Miyoshi
Session: Poster display session
Resources:
Abstract
100P - Clinical impact and carcinogenic mechanism of NCAPG overexpression in colon cancer
Presenter: Kai-Yuan Lin
Session: Poster display session
Resources:
Abstract
101P - Combined cellular immunotherapy and chemotherapy improves clinical outcome and displays safety in the treatment of patients with colorectal cancer
Presenter: Chang Wang
Session: Poster display session
Resources:
Abstract
102P - Clinical features of anorectal cancer in patients with Crohn’s disease: Japanese single center study
Presenter: Kazuhiro Watanabe
Session: Poster display session
Resources:
Abstract
103P - Contrast-enhanced CT-based textural parameters as potential prognostic factors of survival for colorectal cancer patients receiving targeted therapy
Presenter: Yanfei Yang
Session: Poster display session
Resources:
Abstract
104P - Prognostic significance of tumour location to the oncologic outcome of colon cancer
Presenter: Sare Hosseini
Session: Poster display session
Resources:
Abstract
105P - Detection and clinical significance of circulating tumour cells in patients with rectal cancer
Presenter: Shuohui Dong
Session: Poster display session
Resources:
Abstract
106P - The risk of malignization incidence in patients with polyps and polyposis of the colon and rectum
Presenter: Yakov Ten
Session: Poster display session
Resources:
Abstract